Biogen’s Opt-In On Roche’s CD20 Drugs Is Gift That Keeps On Giving

Royalties From Blockbuster Portfolio Amount To Billions

Roche has enjoyed decades-long success with its string of CD20-targeting drugs – and thanks to a legacy opt-in, so has Biogen.

Biogen
Biogen is looking for ways to prop up its income as Aduhelm fails to deliver • Source: Alamy

Beleaguered by its disastrous launch of Alzheimer’s drug Aduhelm (aducanumab), Biogen was able to muster some good news for investors this week, including a new opt-in to co-develop and co-market mosunetuzumab, a promising Roche drug.

The opt-in could prove to be a lifeline for Biogen, and builds on a long-running revenue stream the US company...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip